Physician profile
Lynn Devries
NPI 1215338819
$1,879.44
in general payments reported to CMS, 2019-2025
30 companies · $524 in 2025
The $524 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.92 · 2022: $596 · 2023: $455 · 2024: $287 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $325.07 | 2023-2025 | Veozah |
| Abbvie INC. | $306.83 | 2022-2025 | |
| Exeltis, USA INC. | $273.56 | 2021-2024 | Slynd |
| Pfizer INC. | $115.99 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $79.97 | 2022-2023 | Gardasil 9 |
| Lilly USA, LLC | $59.73 | 2025 | Mounjaro, Kisunla, Zepbound |
| Exact Sciences Corporation | $55.59 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $53.65 | 2025 | Airsupra, Farxiga |
| Ascend Therapeutics US, LLC | $52.73 | 2023 | |
| Organon LLC | $52.43 | 2022 | |
| Novo Nordisk INC | $41.41 | 2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $40.77 | 2024-2025 | |
| Millicent US INC | $40.73 | 2024-2025 | Intrarosa |
| Coopersurgical, INC. | $34.05 | 2022 | |
| Kerecis Limited | $33.64 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $30.58 | 2025 | Quzyttir |
| Therapeuticsmd, INC. | $27.24 | 2022 | |
| Glaxosmithkline, LLC. | $26.29 | 2025 | Trelegy Ellipta |
| Mylan Pharmaceuticals INC. | $22.49 | 2022 | |
| Lundbeck LLC | $22.25 | 2025 | Vyepti |
| Aimmune Therapeutics, INC. | $21.77 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.21 | 2025 | |
| Evofem Biosciences, INC. | $20.73 | 2022 | |
| Esperion Therapeutics, INC. | $19.99 | 2025 | Nexletol |
| Boston Scientific Corporation | $19.97 | 2025 | General - Pain Management |
| Myovant Sciences INC. | $17.63 | 2022 | |
| Mayne Pharma Commercial LLC | $17.36 | 2022 | |
| Agile Therapeutics, INC. | $16.78 | 2023 | Twirla |
| Smith+Nephew, INC. | $15.36 | 2023 | Pico, Renasys Touch |
| Ethicon US, LLC | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Devries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.